

# Peter Bader

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9361733/publications.pdf>

Version: 2024-02-01

301  
papers

14,495  
citations

32410

55  
h-index

27587

110  
g-index

310  
all docs

310  
docs citations

310  
times ranked

15168  
citing authors

#	ARTICLE	IF	CITATIONS
1	Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia. <i>Blood Cancer Discovery</i> , 2022, 3, 66-81.	2.6	70
2	Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. <i>Blood Advances</i> , 2022, 6, 1004-1014.	2.5	22
3	A New Perspective for Bone Tissue Engineering: Human Mesenchymal Stromal Cells Well-Survive Cryopreservation on $\beta$ -TCP Scaffold and Show Increased Ability for Osteogenic Differentiation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1425.	1.8	2
4	Safe transfer of pediatric patients from hematopoietic stem cell transplant unit into the pediatric intensive care unit: views of nurses and physicians. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	0
5	Understanding the Role of LFA-1 in Leukocyte Adhesion Deficiency Type I (LAD I): Moving towards Inflammation?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3578.	1.8	7
6	SARS-CoV-2-specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccination. <i>European Journal of Immunology</i> , 2022, 52, 1194-1197.	1.6	9
7	CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. <i>Leukemia</i> , 2022, 36, 1525-1532.	3.3	27
8	Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 366.e1-366.e7.	0.6	10
9	Psychometric properties of the Activities Scale for Kids-performance after allogeneic hematopoietic stem cell transplantation in adolescents and children. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 41-51.	1.0	3
10	ABO incompatible graft management in pediatric transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 84-90.	1.3	3
11	The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG. <i>Bone Marrow Transplantation</i> , 2021, 56, 257-266.	1.3	11
12	Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 295-307.	0.8	163
13	Stem Cell Transplantation for Diamond-Blackfan Anemia. A Retrospective Study on Behalf of the Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplantation Group (EBMT). <i>Transplantation and Cellular Therapy</i> , 2021, 27, 274.e1-274.e5.	0.6	14
14	Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor. <i>Cancers</i> , 2021, 13, 1443.	1.7	7
15	Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site. <i>Journal of Translational Medicine</i> , 2021, 19, 145.	1.8	15
16	Depletion of CD45RA+ T cells: Advantages and disadvantages of different purification methods. <i>Journal of Immunological Methods</i> , 2021, 492, 112960.	0.6	1
17	Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2021, 56, 2732-2741.	1.3	24
18	Specialized Pediatric Palliative Care Services in Pediatric Hematopoietic Stem Cell Transplant Centers. <i>Children</i> , 2021, 8, 615.	0.6	5

#	ARTICLE	IF	CITATIONS
19	Supportive Care During Pediatric Hematopoietic Stem Cell Transplantation: Prevention of Infections. A Report From Workshops on Supportive Care of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Frontiers in Pediatrics</i> , 2021, 9, 705179.	0.9	22
20	The Reticulocyte Hemoglobin Equivalent as a Screening Marker for Iron Deficiency and Iron Deficiency Anemia in Children. <i>Journal of Clinical Medicine</i> , 2021, 10, 3506.	1.0	9
21	The incidence and type of cancer in patients with ataxia-telangiectasia via a retrospective single-centre study. <i>British Journal of Haematology</i> , 2021, 194, 879-887.	1.2	8
22	Simple Measurement of IgA Predicts Immunity and Mortality in Ataxia-Telangiectasia. <i>Journal of Clinical Immunology</i> , 2021, 41, 1878-1892.	2.0	9
23	How can fertility counseling be implemented for every newly diagnosed pediatric patient facing gonadotoxic treatment? A single-center experience. <i>Annals of Hematology</i> , 2021, 100, 2831-2841.	0.8	3
24	Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. <i>Nature Medicine</i> , 2021, 27, 1806-1817.	15.2	79
25	Improved Therapeutic Approaches are Needed to Manage Graft-versus-Host Disease. <i>Clinical Drug Investigation</i> , 2021, 41, 929-939.	1.1	6
26	Minimal Residual Disease Prior to and After Hematopoietic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia: What Level of Negativity Is Relevant?. <i>Frontiers in Pediatrics</i> , 2021, 9, 777108.	0.9	8
27	Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I and III. <i>Blood Advances</i> , 2021, 5, 262-273.	2.5	9
28	Potential Impact of Treatment with Inotuzumab Ozogamicin on Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 3824-3824.	0.6	3
29	Outcome of Allogeneic HSCT after Chemo-Based Conditioning in Infants with Acute Myeloid Leukemia in First Complete Remission: A Multicenter EBMT-PDWP Study. <i>Blood</i> , 2021, 138, 2862-2862.	0.6	0
30	Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?. <i>Frontiers in Pediatrics</i> , 2021, 9, 784024.	0.9	13
31	Hematopoietic stem cell transplantation for children with acute myeloid leukemia—results of the AML SCT-BFM 2007 trial. <i>Leukemia</i> , 2020, 34, 613-624.	3.3	19
32	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , 2020, 55, 485-495.	1.3	61
33	Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 441-451.	1.3	22
34	Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. <i>Bone Marrow Transplantation</i> , 2020, 55, 126-136.	1.3	196
35	Incidence and outcome of Kaposi sarcoma after hematopoietic stem cell transplantation: a retrospective analysis and a review of the literature, on behalf of infectious diseases working party of EBMT. <i>Bone Marrow Transplantation</i> , 2020, 55, 110-116.	1.3	15
36	Guidance to Bone Morbidity in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e27-e37.	2.0	6

#	ARTICLE	IF	CITATIONS
37	Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial. <i>Leukemia</i> , 2020, 34, 1694-1700.	3.3	24
38	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Haematologica</i> , 2020, 105, 297-316.	1.7	230
39	ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma. <i>Frontiers in Immunology</i> , 2020, 11, 581468.	2.2	22
40	Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. <i>Blood Cancer Journal</i> , 2020, 10, 77.	2.8	65
41	Unstimulated apheresis for chimeric antigen receptor manufacturing in pediatric/adolescent acute lymphoblastic leukemia patients. <i>Journal of Clinical Apheresis</i> , 2020, 35, 398-405.	0.7	15
42	Long-term pulmonary function testing in pediatric bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. <i>Pediatric Pulmonology</i> , 2020, 55, 1725-1735.	1.0	17
43	Favorable outcomes of hematopoietic stem cell transplantation in children and adolescents with Diamond-Blackfan anemia. <i>Blood Advances</i> , 2020, 4, 1760-1769.	2.5	27
44	Pediatric acute graft-versus-host disease prophylaxis and treatment: surveyed real-life approach reveals dissimilarities compared to published recommendations. <i>Transplant International</i> , 2020, 33, 762-772.	0.8	19
45	Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies. <i>Bone Marrow Transplantation</i> , 2020, 55, 1996-2007.	1.3	18
46	Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy? A multicenter EBMT-PDWP study. <i>Bone Marrow Transplantation</i> , 2020, 55, 1540-1551.	1.3	42
47	Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants: two-arm phase I/II study (MOZAIC). <i>Bone Marrow Transplantation</i> , 2020, 55, 1744-1753.	1.3	12
48	Single Center Real Life Experiences in the Treatment of Pediatric, Adolescent and Young Adult ALL Patients Using Commercially Available CAR-T-Cells in Germany – Susceptibility to Bridging Chemotherapy Predicts Response.. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S262.	2.0	1
49	Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28523.	0.8	8
50	Tracking of Infused Mesenchymal Stem Cells in Injured Pulmonary Tissue in Atm-Deficient Mice. <i>Cells</i> , 2020, 9, 1444.	1.8	7
51	Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 1126-1136.	1.3	23
52	The Phenotype and Functional Activity of Mesenchymal Stromal Cells in Pediatric Patients with Non-Malignant Hematological Diseases. <i>Cells</i> , 2020, 9, 431.	1.8	3
53	Serving his patients with passion and dedication – Obituary to Prof. Dr. Dr. h.c. Dietrich Niethammer. <i>Bone Marrow Transplantation</i> , 2020, 55, 1209-1210.	1.3	0
54	Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1223-1231.	1.7	34

#	ARTICLE	IF	CITATIONS
55	Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of <scp>EBMT</scp> group. American Journal of Hematology, 2020, 95, 809-816.	2.0	30
56	A systematic approach to the endocrine care of survivors of pediatric hematopoietic stem cell transplantation. Cancer and Metastasis Reviews, 2020, 39, 69-78.	2.7	9
57	Favorable immune recovery and low rate of GvHD in children transplanted with partially T cell-depleted PBSC grafts. Bone Marrow Transplantation, 2019, 54, 53-62.	1.3	3
58	Myeloablative Unrelated Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia. Biology of Blood and Marrow Transplantation, 2019, 25, 2438-2446.	2.0	7
59	The German National Registry of Primary Immunodeficiencies (2012â€“2017). Frontiers in Immunology, 2019, 10, 1272.	2.2	71
60	Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties. Frontiers in Immunology, 2019, 10, 1570.	2.2	48
61	Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT. Bone Marrow Transplantation, 2019, 54, 2060-2071.	1.3	6
62	Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10â€“14 years as compared with those aged 15â€“17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study. European Journal of Cancer, 2019, 122, 61-71.	1.3	14
63	Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 1710-1718.	5.1	65
64	Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematology, the, 2019, 6, e573-e584.	2.2	140
65	Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics. Journal of Clinical Oncology, 2019, 37, 3493-3506.	0.8	18
66	Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2019, 25, 1786-1791.	2.0	42
67	Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells. Frontiers in Immunology, 2019, 10, 1218.	2.2	18
68	Psychophysical effects of an exercise therapy during pediatric stem cell transplantation: a randomized controlled trial. Bone Marrow Transplantation, 2019, 54, 1827-1835.	1.3	21
69	Presence of centromeric but absence of telomeric group B KIR haplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALL. Bone Marrow Transplantation, 2019, 54, 1847-1858.	1.3	16
70	Allogeneic hematopoietic stem cell transplantation from unrelated donors is associated with higher infection rates in children with acute lymphoblastic leukemiaâ€”A prospective international multicenter trial on behalf of the BFMâ€™SG and the EBMTâ€™PDWP. American Journal of Hematology, 2019, 94, 880-890.	2.0	9
71	Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease. Haematologica, 2019, 104, e543-e546.	1.7	47
72	Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions. Biology of Blood and Marrow Transplantation, 2019, 25, 1281-1292.	2.0	28

#	ARTICLE	IF	CITATIONS
73	Genetically engineered CAR NK cells display selective cytotoxicity against FLT3 <sup>+</sup> ALL and inhibit <i>in vivo</i> leukemia growth. <i>International Journal of Cancer</i> , 2019, 145, 1935-1945.	2.3	60
74	Transplant center practices for psychosocial assessment and management of pediatric hematopoietic stem cell donors. <i>Bone Marrow Transplantation</i> , 2019, 54, 1780-1788.	1.3	10
75	Clinical Use of Mesenchymal Stromal Cells in the Treatment of Acute Graft-versus-Host Disease. <i>Transfusion Medicine and Hemotherapy</i> , 2019, 46, 27-34.	0.7	67
76	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. <i>Bone Marrow Transplantation</i> , 2019, 54, 1525-1552.	1.3	218
77	Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: Updated Analysis of the ELIANA Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S126-S127.	2.0	16
78	Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets. <i>Blood Advances</i> , 2019, 3, 3143-3156.	2.5	4
79	More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. <i>Blood Advances</i> , 2019, 3, 3393-3405.	2.5	81
80	The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their <i>ex vivo</i> Expansion and Cytotoxic Potential Against Neuroblastoma: Perspective for Optimized Immunotherapy Post Haploidentical Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 2816.	2.2	37
81	Hematopoietic Stem Cell Transplantation Restores Naïve T-Cell Populations in Atm-Deficient Mice and in Preemptively Treated Patients With Ataxia-Telangiectasia. <i>Frontiers in Immunology</i> , 2019, 10, 2785.	2.2	12
82	Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM" Outcome Report of 92 Patients. <i>Cells</i> , 2019, 8, 1577.	1.8	38
83	Solid organ transplantation after hematopoietic stem cell transplantation in childhood: A multicentric retrospective survey. <i>American Journal of Transplantation</i> , 2019, 19, 1798-1805.	2.6	9
84	Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients. <i>JAMA Oncology</i> , 2019, 5, 229.	3.4	33
85	Beneficial role of CD8 <sup>+</sup> T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting. <i>Bone Marrow Transplantation</i> , 2019, 54, 867-876.	1.3	8
86	AlloHSCT in paediatric ALL and AML in complete remission: improvement over time impacted by accreditation?. <i>Bone Marrow Transplantation</i> , 2019, 54, 737-745.	1.3	4
87	Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO). <i>Blood</i> , 2019, 134, 1294-1294.	0.6	7
88	Adoptive cellular immunotherapy for refractory childhood cancers: a single center experience. <i>Oncotarget</i> , 2019, 10, 6138-6151.	0.8	3
89	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents with GATA2-Related Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 2033-2033.	0.6	0
90	Haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk soft tissue sarcomas: results of a single-center prospective trial. <i>Bone Marrow Transplantation</i> , 2018, 53, 891-894.	1.3	10

#	ARTICLE	IF	CITATIONS
91	Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). Bone Marrow Transplantation, 2018, 53, 852-862.	1.3	77
92	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine, 2018, 378, 439-448.	13.9	3,680
93	Low Body Mass Index Is Associated with Increased Risk of Acute GVHD after Umbilical Cord Blood Transplantation in Children and Young Adults with Acute Leukemia: A Study on Behalf of Eurocord and the EBMT Pediatric Disease Working Party. Biology of Blood and Marrow Transplantation, 2018, 24, 799-805.	2.0	22
94	Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation. Bone Marrow Transplantation, 2018, 53, 1548-1552.	1.3	6
95	Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplantation, 2018, 53, 1139-1148.	1.3	117
96	Second Hematopoietic Stem Cell Transplantation for Post-Transplantation Relapsed Acute Leukemia in Children: A Retrospective EBMT-PDWP Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1629-1642.	2.0	44
97	Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	25
98	Impact of the initial fitness level on the effects of a structured exercise therapy during pediatric stem cell transplantation. Pediatric Blood and Cancer, 2018, 65, e26851.	0.8	26
99	CD34 <sup>+</sup> selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation. British Journal of Haematology, 2018, 180, 90-99.	1.2	39
100	Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial. British Journal of Haematology, 2018, 180, 82-89.	1.2	50
101	Pre-emptive Allogeneic Hematopoietic Stem Cell Transplantation in Ataxia Telangiectasia. Frontiers in Immunology, 2018, 9, 2495.	2.2	41
102	Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma. Frontiers in Immunology, 2018, 9, 2743.	2.2	25
103	Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood Cancer Journal, 2018, 8, 80.	2.8	68
104	Serum ferritin is not a reliable predictor to determine iron overload in thalassemia major patients post-hematopoietic stem cell transplantation. European Journal of Haematology, 2018, 101, 791-797.	1.1	9
105	Joint Modeling of Immune Reconstitution Post Haploidentical Stem Cell Transplantation in Pediatric Patients With Acute Leukemia Comparing CD34 <sup>+</sup> -Selected to CD3/CD19-Depleted Grafts in a Retrospective Multicenter Study. Frontiers in Immunology, 2018, 9, 1841.	2.2	20
106	Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes. Biology of Blood and Marrow Transplantation, 2018, 24, 1848-1855.	2.0	27
107	Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma. Cytotherapy, 2018, 20, 839-850.	0.3	7
108	An Exponential Regression Model Reveals the Continuous Development of B Cell Subpopulations Used as Reference Values in Children. Frontiers in Pediatrics, 2018, 6, 121.	0.9	0

#	ARTICLE	IF	CITATIONS
109	Low incidence of symptomatic osteonecrosis after allogeneic HSCT in children with high-risk or relapsed ALL – results of the ALL-SCT 2003 trial. British Journal of Haematology, 2018, 183, 104-109.	1.2	12
110	Hematopoietic Cell Transplantation in Thalassemia and Sickle Cell Disease: Report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry: 2000-2017. Blood, 2018, 132, 168-168.	0.6	9
111	High Molecular Remission Rate in Pediatric Patients (pts) with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (r/r ALL) Treated with Blinatumomab: Rialto an Open-Label, Multicenter, Expanded Access Study. Blood, 2018, 132, 1375-1375.	0.6	3
112	Results of a Prospective, Multicenter, Phase I/II Clinical Study in Pediatric and Adult Patients Using TCR Alpha/Beta and CD19 Depleted Haploidentical Hematopoietic Stem Cell Grafts Following Reduced-Intensity Conditioning. Blood, 2018, 132, 604-604.	0.6	3
113	Pregnancy Rates and Pregnancy Outcomes after Hematopoietic Stem Cell Transplantation in Childhood: a Cross-Sectional Survey of the EBMT Pediatric WP. Blood, 2018, 132, 3418-3418.	0.6	2
114	Children and Adults with Steroid-Refractory Acute Graft-Versus-Host Disease Respond to Treatment with the Mesenchymal Stroma Cell Preparation "MSC-FFM": Treatment Results for 92 Consecutive Patients. Blood, 2018, 132, 603-603.	0.6	1
115	Alternative Donor Hematopoietic Stem Cell Transplantation for Sickle Cell Disease in Europe. Blood, 2018, 132, 4645-4645.	0.6	3
116	Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia. Blood, 2018, 132, 895-895.	0.6	70
117	Conception and Pregnancy Outcomes after Haematopoietic Stem Cell Transplant: A Retrospective Study from the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Blood, 2018, 132, 2139-2139.	0.6	3
118	Molecular Detection of Minimal Residual Disease Precedes Morphological Relapse and Could be Used to Identify Relapse in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia Patients Treated with Tisagenlecleucel. Blood, 2018, 132, 1551-1551.	0.6	12
119	Long-Term Follow-up of the Randomized Controlled Study in Patients with Newly Diagnosed Severe Aplastic Anemia Treated with ATG, Cyclosporine, with or without G-CSF: On Behalf of the SAA Working Party of the EBMT. Blood, 2018, 132, 1307-1307.	0.6	0
120	Stem Cell Transplantation for Pediatric Patients with Non-Anaplastic Peripheral T-Cell Lymphoma on Behalf of the EBMT-Pediatric Diseases Working Party. Blood, 2018, 132, 5787-5787.	0.6	0
121	Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia: On Behalf of Eurocord, Ctiwp and PDWP of EBMT. Blood, 2018, 132, 3369-3369.	0.6	0
122	The Optimal Alternative Donor Transplant for Pediatric Patients with Acute Leukemia: A Comparison between Alfa-Beta T-Cell and B-Cell Depleted Haplo-SCT and UCBT. Blood, 2018, 132, 3462-3462.	0.6	0
123	Prospective Clinical Phase II Results on Treosulfan-Based Conditioning Treatment of 70 Paediatric Patients with Haematological Malignancies. Blood, 2018, 132, 3354-3354.	0.6	0
124	Generation and flow cytometric quality control of clinical-scale TCR $\alpha$ /CD19-depleted grafts. Cytometry Part B - Clinical Cytometry, 2017, 92, 126-135.	0.7	11
125	Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission. Biology of Blood and Marrow Transplantation, 2017, 23, 1350-1358.	2.0	25
126	Monitoring of MRD before and after Allogeneic Hematopoietic Cell Transplantation (HCT) of Childhood ALL by FC and RQ-PCR: A Retrospective Assessment on Behalf of the Pdpw of the Ebmt, the Cog, the Pbmtc, the I-Bfm and the Westhafen-Intercontinental-Group. Biology of Blood and Marrow Transplantation, 2017, 23, S22-S23.	2.0	0



#	ARTICLE	IF	CITATIONS
127	Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 467-474.	2.0	41
128	Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. <i>Blood</i> , 2017, 129, 1548-1556.	0.6	340
129	Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S263-S264.	0.2	41
130	An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 6478-6486.	3.2	28
131	Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 87-95.	2.0	27
132	Unrelated Cord Blood Transplantation for Acute Leukemia Diagnosed in the First Year of Life: Outcomes and Risk Factor Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 96-102.	2.0	5
133	Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. <i>Cytotherapy</i> , 2017, 19, 235-249.	0.3	142
134	Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. <i>Blood Advances</i> , 2017, 1, 2742-2755.	2.5	151
135	The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Pharmacology</i> , 2017, 8, 451.	1.6	8
136	Treatment of Infantile Inflammatory Bowel Disease and Autoimmunity by Allogeneic Stem Cell Transplantation in LPS-Responsive Beige-Like Anchor Deficiency. <i>Frontiers in Immunology</i> , 2017, 8, 52.	2.2	24
137	Development of Three Different NK Cell Subpopulations during Immune Reconstitution after Pediatric Allogeneic Hematopoietic Stem Cell Transplantation: Prognostic Markers in GvHD and Viral Infections. <i>Frontiers in Immunology</i> , 2017, 8, 109.	2.2	30
138	The Smac Mimetic BV6 Improves NK Cell-Mediated Killing of Rhabdomyosarcoma Cells by Simultaneously Targeting Tumor and Effector Cells. <i>Frontiers in Immunology</i> , 2017, 8, 202.	2.2	18
139	A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma. <i>Frontiers in Immunology</i> , 2017, 8, 676.	2.2	70
140	Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children. <i>Oncotarget</i> , 2017, 8, 66137-66153.	0.8	34
141	Outcome of Children Developing Grade III-IV Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Report on Behalf of the EBMT Paediatric Diseases Working Party. <i>Blood</i> , 2017, 130, 76-76.	0.6	0
142	Transplantation Outcome By Disease Risk and Donor Type over Time: An Analysis of 100,000 Allogeneic Stem Cell Transplantation on Behalf of the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2017, 130, 668-668.	0.6	0
143	Myeloablative Conditioning for First Allogeneic Hematopoietic Stem Cell Transplantation in Children with ALL: Total Body Irradiation or Chemotherapy? - a Multicenter EBMT-PDWP Study. <i>Blood</i> , 2017, 130, 911-911.	0.6	1
144	Relation between Acute GVHD and NK Cell Subset Reconstitution Following Allogeneic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2016, 7, 595.	2.2	36

#	ARTICLE	IF	CITATIONS
145	Atypical Manifestation of LPS-Responsive Beige-Like Anchor Deficiency Syndrome as an Autoimmune Endocrine Disorder without Enteropathy and Immunodeficiency. <i>Frontiers in Pediatrics</i> , 2016, 4, 98.	0.9	18
146	Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival. <i>International Journal of Cancer</i> , 2016, 139, 1799-1809.	2.3	51
147	Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia. <i>Haematologica</i> , 2016, 101, 741-746.	1.7	24
148	Defibrotide for Prophylaxis of Hepatic Veno-Occlusive Disease in Pediatric Hematopoietic Stem Cell Transplantation: Subanalysis Data from an Open-Label, Phase III, Randomized Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S25-S26.	2.0	2
149	Preemptive Treatment of Minimal Residual Disease (MRD) with IL-15-Activated Cytokine-Induced Killer Cells for the Prevention of Relapse in Leukemia Patients after Allogeneic Stem Cell Transplantation – Results of a Pilot Study. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S43.	2.0	2
150	The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2016, 127, 3281-3290.	0.6	83
151	Specific phenotype and function of CD56-expressing innate immune cell subsets in human thymus. <i>Journal of Leukocyte Biology</i> , 2016, 100, 1297-1310.	1.5	3
152	Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 4381-4389.	0.8	478
153	Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey. <i>Haematologica</i> , 2016, 101, 985-994.	1.7	78
154	Optimization of individualized graft composition: CD3/CD19 depletion combined with CD34 selection for haploidentical transplantation. <i>Transfusion</i> , 2016, 56, 2336-2345.	0.8	12
155	Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy. <i>Haematologica</i> , 2016, 101, e153-e156.	1.7	36
156	In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy. <i>Journal of Translational Medicine</i> , 2016, 14, 264.	1.8	7
157	Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells. <i>Pediatric Blood and Cancer</i> , 2016, 63, 2230-2239.	0.8	16
158	Epidemiology, risk factors, and prognosis of capillary leak syndrome in pediatric recipients of stem cell transplants: a retrospective single-center cohort study. <i>Pediatric Transplantation</i> , 2016, 20, 1132-1136.	0.5	22
159	Selection and expansion of natural killer cells for NK cell-based immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 477-484.	2.0	137
160	Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2016, 128, 221-221.	0.6	62
161	TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: First Results of a Prospective Multicenter Phase I/II Clinical Trial. <i>Blood</i> , 2016, 128, 389-389.	0.6	11
162	Monitoring of Minimal Residual Disease before and after Allogeneic Stem Cell Transplantation Childhood ALL - a Retrospective Assessment on Behalf of the PDWP of the EBMT, the COG, PBMTc, the I-BFM and the Westhafen-Intercontinental-Group. <i>Blood</i> , 2016, 128, 985-985.	0.6	2

#	ARTICLE	IF	CITATIONS
163	The Disease Risk Index Is a Robust Tool for Allogeneic Hematopoietic Stem Cell Transplantation Risk Stratification: An Independent Validation Study on a Large Cohort of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 988-988.	0.6	1
164	Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow. <i>Oncotarget</i> , 2016, 7, 70959-70968.	0.8	19
165	Safety and Tolerability of Donor Type Red Blood Cell Transfusion before Allogeneic Stem Cell Transplantation in Children with Major ABO Mismatch. <i>Blood</i> , 2016, 128, 3415-3415.	0.6	1
166	Fertility Preservation in Pediatric and Adolescent Patients Undergoing HSCT: a Cross-Sectional Survey of the EBMT Pediatric WP. <i>Blood</i> , 2016, 128, 4611-4611.	0.6	0
167	Contemporary Conditioning Regimen before Allogeneic Stem Cell Transplantation for Children with Non-Malignant Diseases. <i>Blood</i> , 2016, 128, 3398-3398.	0.6	0
168	Development of a Risk Score for Prediction of Overall Survival Following Umbilical Cord Blood Transplantation in Acute Leukemia Patients: A Study from the Acute Leukemia Working Party (WP) and Paediatric Disease WP of the European Society for Blood and Marrow Transplantation (EBMT), and Eurocord. <i>Blood</i> , 2016, 128, 1169-1169.	0.6	2
169	Decentralized Manufacture of TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Grafts for Children within a Multicenter Phase I/II Clinical Trial. <i>Blood</i> , 2016, 128, 2172-2172.	0.6	0
170	Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia Relapsing after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 601-601.	0.6	0
171	Preemptive Immunotherapy Based on Post-Transplant Chimerism and MRD Monitoring Is an Effective Strategy to Prevent Relapse after Allogeneic Stem Cell Transplantation in Children with ALL: A Single Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S209.	2.0	0
172	Similar outcome of upfront unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. <i>British Journal of Haematology</i> , 2015, 171, 585-594.	1.2	146
173	NK Cell Subgroups, Phenotype, and Functions After Autologous Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2015, 6, 583.	2.2	19
174	$\beta$ -D-Glucan Screening for Detection of Invasive Fungal Disease in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2605-2610.	1.8	46
175	Monitoring of Minimal Residual Disease After Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the ALL-BFM-SCT 2003 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1275-1284.	0.8	110
176	Patterns of monocyte subpopulations and their surface expression of HLA-DR during adverse events after hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2015, 94, 825-836.	0.8	17
177	Human leukocyte antigen DR surface expression on CD14+ monocytes during adverse events after hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2015, 94, 265-273.	0.8	9
178	Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus. <i>Cytotherapy</i> , 2015, 17, 1139-1151.	0.3	16
179	Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. <i>Blood</i> , 2015, 125, 1986-1994.	0.6	127
180	Stem-Cell Transplantation in Children With Acute Lymphoblastic Leukemia: A Prospective International Multicenter Trial Comparing Sibling Donors With Matched Unrelated Donors—The ALL-SCT-BFM-2003 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1265-1274.	0.8	186

#	ARTICLE	IF	CITATIONS
181	Cotransplantation of preactivated mesenchymal stromal cells with hematopoietic stem cells improves T-cell regeneration. <i>Cytotherapy</i> , 2015, 17, S8.	0.3	0
182	Challenges in the harmonization of immune monitoring studies and trial design for cell-based therapies in the context of hematopoietic cell transplantation for pediatric cancer patients. <i>Cytotherapy</i> , 2015, 17, 1667-1674.	0.3	15
183	Prospective Validation of a New Method of Monitoring Minimal Residual Disease in Childhood Acute Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 1353-1359.	3.2	48
184	Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 402-411.	2.0	8
185	Defibrotide for Prophylaxis of Hepatic Veno-Occlusive Disease in Pediatric Hematopoietic Stem Cell Transplantation: Subanalysis Data from an Open-Label, Phase III, Randomized Trial. <i>Blood</i> , 2015, 126, 4310-4310.	0.6	3
186	Phase I/II Study of the Deacetylase Inhibitor Panobinostat As Maintenance Therapy after an Allogeneic Stem Cell Transplantation in Patients with High-Risk MDS or AML: The Panobest-Trial. <i>Blood</i> , 2015, 126, 4344-4344.	0.6	16
187	An Accelerated CD8+, but Not CD4+, T-Cell Reconstitution Associates with a More Favorable Outcome Following HLA-Haploidentical HSCT: Results from a Retrospective Study of the Cell Therapy and Immunobiology Working Party of the EBMT. <i>Blood</i> , 2015, 126, 1929-1929.	0.6	0
188	A Machine Learning Based Model to Predict Two-Year Leukemia Free Survival in Cord Blood Transplantation for Acute Leukemia - a Data Mining Study, on Behalf of Eurocord, Cord Blood Committee and the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2015, 126, 3211-3211.	0.6	3
189	Treatment of Iron Overload in Transfusion-Dependent Anemias Post Hematopoietic Stem Cell Transplantation: When to Start? When to Stop?. <i>Blood</i> , 2015, 126, 3369-3369.	0.6	0
190	Impact of GvHD and Other Patient-, Disease-, Donor and Transplantation-Related Factors on 5 Year Relapse after Unrelated Cord Blood Transplantation for Children with Acute Lymphoblastic Leukemia in Remission. <i>Blood</i> , 2015, 126, 4384-4384.	0.6	0
191	Hematopoietic stem cell transplantation and immunotherapy for pediatric acute myeloid leukemia: an open challenge. <i>Expert Review of Hematology</i> , 2014, 7, 291-300.	1.0	6
192	SMAC Mimetic BV6 Enables Sensitization of Resistant Tumor Cells but also Affects Cytokine-Induced Killer (CIK) Cells: A Potential Challenge for Combination Therapy. <i>Frontiers in Pediatrics</i> , 2014, 2, 75.	0.9	14
193	Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion. <i>Cytotherapy</i> , 2014, 16, 835-844.	0.3	21
194	HLA Identical Siblings Are the Best Donors for Children with ALL. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S179-S180.	2.0	0
195	Odontoid infiltration and spinal compression in Farber Disease: reversal by haematopoietic stem cell transplantation. <i>European Journal of Pediatrics</i> , 2014, 173, 1399-1403.	1.3	15
196	Monitoring of Hematopoietic Chimerism after Transplantation for Pediatric Myelodysplastic Syndrome: Real-Time or Conventional Short Tandem Repeat PCR in Peripheral Blood or Bone Marrow?. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1918-1925.	2.0	29
197	Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 821-833.	2.0	26
198	Quantitative Monitoring of Minimal Residual Disease after Allogeneic Stem Cell Transplantation in Relapsed Childhood ALL Allows the Identification of Impending Relapse – Results of the ALL BFM SCT 2003 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S85-S86.	2.0	0

#	ARTICLE	IF	CITATIONS
199	Comparison Between Related T-Cell Depleted HLA-Haploidentical Stem Cell Transplantation (TCD-Haplo) and Umbilical Cord Blood Transplantation (UCBT) in Pediatric Patients with Acute Leukemia, a Eurocord, PDWP-EBMT Study. <i>Blood</i> , 2014, 124, 1215-1215.	0.6	2
200	Fetomaternal Microchimerism Is Associated with Better Outcome in Haploidentical Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 1242-1242.	0.6	2
201	Phase 1/2 Study in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Receiving Blinatumomab Treatment. <i>Blood</i> , 2014, 124, 2292-2292.	0.6	17
202	Initial Results from a Phase 2 Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3703-3703.	0.6	19
203	Myeloablative Chemo-Conditioning for First Hematopoietic STEM CELL Transplantation in Children with ACUTE Lymphoblastic Leukemia in First or Second Remission. <i>Blood</i> , 2014, 124, 546-546.	0.6	14
204	Similar Outcome of Upfront Unrelated and Matched Sibling Donor Hematopoietic Stem Cell Transplantation in Idiopathic Aplastic Anaemia of Childhood and Adolescence: A Cohort Controlled Study on Behalf of the UK Paediatric BMT WP, of the PD WP and of the SAA WP of the EBMT. <i>Blood</i> , 2014, 124, 256-256.	0.6	0
205	CMV-Specific Cytokine-Induced Killer Cells Comprise Concomitant Cytotoxicity Against Leukemia and Cytomegalovirus. <i>Blood</i> , 2014, 124, 5814-5814.	0.6	0
206	Repetitive Infusions of Cytokine-Induced Killer (CIK) Cells for Treatment of Impending Relapse in High-Risk Leukemia Patients after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 2438-2438.	0.6	0
207	Long-Term Outcome of Preemptive Immunotherapy Based on Post-Transplant Chimerism and MRD Monitoring after Allogeneic Stem Cell Transplantation in Children with Acute Lymphoblastic Leukemia: A Single Center Experience. <i>Blood</i> , 2014, 124, 3953-3953.	0.6	0
208	Outcomes after Double Umbilical Cord Blood Transplantation in Children: A Survey on Behalf of Eurocord and PDWP-EBMT. <i>Blood</i> , 2014, 124, 2570-2570.	0.6	0
209	Highlights of the Third International Conference on Immunotherapy in Pediatric Oncology. <i>Pediatric Hematology and Oncology</i> , 2013, 30, 349-366.	0.3	3
210	Allogeneic HSCT from Unrelated and Sibling Donors are Equal for Children with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S228-S229.	2.0	0
211	Incidence and Mortality of Adenovirus Infection After Pediatric Allogeneic SCT – A Comparison Between Bone Marrow and CD3/19 Depleted PBSC. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S242.	2.0	0
212	Clonal analysis of multipotent stromal cells derived from CD271+ bone marrow mononuclear cells: functional heterogeneity and different mechanisms of allosuppression. <i>Haematologica</i> , 2013, 98, 1609-1616.	1.7	41
213	Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing Protocol. <i>Frontiers in Oncology</i> , 2013, 3, 118.	1.3	103
214	Pediatric Fanconi Anemia With Secondary AML: A Retrospective Outcome Report From The German AML-BFM Group. <i>Blood</i> , 2013, 122, 1414-1414.	0.6	1
215	Post-Transplant Maintenance With The Deacetylase Inhibitor Panobinostat In Patients With High-Risk AML Or MDS: Results Of The Phase I Part Of The Panobest Trial. <i>Blood</i> , 2013, 122, 3315-3315.	0.6	6
216	Clinical Impact Of Post-Transplant Chimerism Monitoring In CD33/34 Bone Marrow Subpopulations and Whole Blood In Pediatric AML: Prospective Comparison Of Highly Sensitive Real Time Sequence Polymorphism PCR Versus Gold-Standard Conventional STR-PCR. <i>Blood</i> , 2013, 122, 411-411.	0.6	3

#	ARTICLE	IF	CITATIONS
217	A Phase 1/2 Study Of Blinatumomab In Pediatric Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 70-70.	0.6	20
218	Monitoring of Minimal Residual Disease After Allogeneic Stem Cell Transplantation In Relapsed Childhood ALL Allows The Identification Of Impending Relapse - Results Of The ALL BFM SCT 2003 Trial. <i>Blood</i> , 2013, 122, 1995-1995.	0.6	0
219	Impact Of Prophylaxis With Defibrotide On The Occurrence Of Acute GvHD In Allogeneic HSCT. <i>Blood</i> , 2013, 122, 4591-4591.	0.6	3
220	Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. <i>Lancet</i> , The, 2012, 379, 1301-1309.	6.3	324
221	Sequential Anti-Cytomegalovirus Response Monitoring May Allow Prediction of Cytomegalovirus Reactivation after Allogeneic Stem Cell Transplantation. <i>PLoS ONE</i> , 2012, 7, e50248.	1.1	29
222	Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models. <i>Frontiers in Oncology</i> , 2012, 2, 32.	1.3	36
223	The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. <i>Cytotherapy</i> , 2012, 14, 91-103.	0.3	84
224	Mesenchymal stromal cells derived from CD271+ bone marrow mononuclear cells exert potent allosuppressive properties. <i>Cytotherapy</i> , 2011, 13, 1193-1204.	0.3	29
225	Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescence using CD3/CD19-depleted stem cells. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 331-337.	0.7	46
226	Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 443-452.	0.7	17
227	Natural killer cell activity influences outcome after T cell depleted stem cell transplantation from matched unrelated and haploidentical donors. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 403-411.	0.7	22
228	IL-2 Stimulated but Not Unstimulated NK Cells Induce Selective Disappearance of Peripheral Blood Cells: Concomitant Results to a Phase I/II Study. <i>PLoS ONE</i> , 2011, 6, e27351.	1.1	76
229	Advanced flowcytometric analysis of regulatory T cells: CD127 downregulation early post stem cell transplantation and altered Treg/CD3+CD4+-ratio in severe GvHD or relapse. <i>Journal of Immunological Methods</i> , 2011, 373, 36-44.	0.6	22
230	Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. <i>Blood</i> , 2011, 118, 5681-5688.	0.6	92
231	Updated Long-Term Results of a Randomized Comparison of Prophylactic and Pre-Emptive Imatinib Following Allogeneic Stem Cell Transplantation for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL). <i>Blood</i> , 2011, 118, 247-247.	0.6	5
232	IL-2-activated haploidentical NK cells restore NKG2D-mediated NK cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA. <i>European Journal of Immunology</i> , 2010, 40, 3255-3267.	1.6	77
233	Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. <i>Haematologica</i> , 2010, 95, 1579-1586.	1.7	63
234	CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. <i>Haematologica</i> , 2010, 95, 651-659.	1.7	151

#	ARTICLE	IF	CITATIONS
235	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, Acute Leukemias, and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1107-1111.	2.0	76
236	Allogeneic Hematopoietic Stem Cell Transplantation (SCT) In Children with ALL: Outcome of Matched Sibling Donor SCT (MSD-SCT) Is Equivalent to Unrelated Well Matched Donor HSCT (MD-HSCT) A Report From the Prospective International Multicenter Trial ALL-SCT-BFM 2003. <i>Blood</i> , 2010, 116, 530-530.	0.6	0
237	Successful Haploidentical Stemcell Transplantation In a Patient with Fanconi Anemia and AML.. <i>Blood</i> , 2010, 116, 4586-4586.	0.6	0
238	Outcome of Relapse After Allogeneic Transplantation for Childhood Acute Lymphoblastic Leukemia In Complete Remission. A Study of the Pediatric Diseases and Acute Leukemia Working Parties of the EBMT Group. <i>Blood</i> , 2010, 116, 1291-1291.	0.6	16
239	WT1 Expression at the Diagnosis of Childhood AML Has No Prognostic Value but Corresponds with the Biological Characteristics of Leukemic Cells - Results From European Multicenter Study.. <i>Blood</i> , 2010, 116, 1684-1684.	0.6	0
240	Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 377-384.	0.8	337
241	Adult Stem Cells as an Alternative Source of Multipotential (Pluripotential) Cells in Regenerative Medicine. <i>Current Stem Cell Research and Therapy</i> , 2009, 4, 107-117.	0.6	48
242	Long Term Survival and Relapse Rate After Transplantation of Highly T and B Cell Depleted Stem Cells From Alternative Donors in Pediatric Patients with Acute Lymphatic Leukemia.. <i>Blood</i> , 2009, 114, 4333-4333.	0.6	0
243	Adoptive Transfer of Hexon-Specific T-Cells as a Treatment of Adenovirus Reactivation Following Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 796-796.	0.6	1
244	Stem cell transplantation for polycythemia vera. <i>Pediatric Blood and Cancer</i> , 2008, 50, 124-126.	0.8	8
245	Severe Bullous Pemphigoid in an Infantâ€” Successful Treatment with Rituximab. <i>Pediatric Dermatology</i> , 2008, 25, 462-465.	0.5	47
246	Enumeration of functionally active anti-Aspergillus T-cells in human peripheral blood. <i>Journal of Immunological Methods</i> , 2008, 335, 41-45.	0.6	29
247	Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients. <i>Blood Cells, Molecules, and Diseases</i> , 2008, 40, 33-39.	0.6	40
248	Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. <i>Blood</i> , 2008, 111, 1124-1127.	0.6	33
249	Significant Reduction of Treatment Related Mortality after Stem Cell Transplantation in 647 Children and Adolescents with ALL within BFM Trials during the Last 12 Years: A Long Term Analysis from 1996 to 2007. <i>Blood</i> , 2008, 112, 567-567.	0.6	0
250	Haploidentical Stem Cell Transplantation in Childhood. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 37-44.	0.2	4
251	Sequence Polymorphism Systems for Quantitative Real-Time Polymerase Chain Reaction to Characterize Hematopoietic Chimerismâ€”High Informativity and Sensitivity As Well As Excellent Reproducibility and Precision of Measurement. <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , 2007, 13, 73-84.	1.2	23
252	Hematopoietic Stem Cell Transplantation (HSCT) after a Myeloablative Conditioning Regimen in Children with Refractory Cytopenia (RC): Results of a Retrospective Analysis from the EWOG-MDS Group.. <i>Blood</i> , 2007, 110, 251-251.	0.6	11

#	ARTICLE	IF	CITATIONS
253	Phenotypic and Functional Characterization of Mesenchymal Stromal Cells Derived from CD271+ Bone Marrow Mononuclear Cells and Mesenchymal Stromal Cells Derived through Plastic Adherence.. <i>Blood</i> , 2007, 110, 1921-1921.	0.6	0
254	PRIMARY INTESTINAL ASPERGILLOSIS AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL RESCUE. <i>Pediatric Infectious Disease Journal</i> , 2006, 25, 465-466.	1.1	16
255	Development of an Allele-Specific Minimal Residual Disease Assay for Patients with Juvenile Myelomonocytic Leukemia-Moving beyond Clinical Assessment.. <i>Blood</i> , 2006, 108, 2681-2681.	0.6	3
256	Transplantation of Positive Selected Peripheral Stem Cells with Add-Back of T Cells from Unrelated Donors in Children: Favourable Survival and Low Incidence of GvHD.. <i>Blood</i> , 2006, 108, 2900-2900.	0.6	0
257	The EuroChimerism Concept for a Standardized Approach to Chimerism Analysis Following Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 621-621.	0.6	0
258	Preemptive Immunotherapy with Highly Purified CD56+/CD3 <sup>+</sup> Natural Killer Cells after Haploidentical Stem Cell Transplantation. A Prospective Phase II Study in 2 Centers.. <i>Blood</i> , 2006, 108, 411-411.	0.6	0
259	CD3/CD19 Depleted Grafts for Haploidentical Stem Cell Transplantation in Children: Results of a Pilot Study.. <i>Blood</i> , 2006, 108, 3121-3121.	0.6	11
260	Retransplantation with Stem Cells from Mismatched Related Donors after Graft Rejection in Pediatric Patients.. <i>Blood</i> , 2006, 108, 2955-2955.	0.6	0
261	Outcome of allogeneic stem cell transplantation in children with non-malignant diseases. <i>Haematologica</i> , 2006, 91, 788-94.	1.7	23
262	Simultaneous Control of Third-Degree Graft-Versus-Host Disease and Prevention of Recurrence of Juvenile Myelomonocytic Leukemia (JMML) With 6-Mercaptopurine Following Fulminant JMML Relapse Early After KIR Mismatched Bone Marrow Transplantation. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 672-674.	0.3	4
263	Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy. <i>British Journal of Haematology</i> , 2005, 128, 649-658.	1.2	40
264	Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. <i>British Journal of Haematology</i> , 2005, 128, 774-782.	1.2	116
265	Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2005, 129, 542-549.	1.2	45
266	Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. <i>Investigational New Drugs</i> , 2005, 23, 99-109.	1.2	50
267	Hematopoietic chimerism after allogeneic stem cell transplantation: a comparison of quantitative analysis by automated DNA sizing and fluorescent in situ hybridization. <i>BMC Hematology</i> , 2005, 5, 1.	2.6	8
268	Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. <i>Blood</i> , 2005, 105, 410-419.	0.6	291
269	Graft-Versus-Ewing Sarcoma Effect and Long-Term Remission Induced by Haploidentical Stem-Cell Transplantation in a Patient With Relapse of Metastatic Disease. <i>Journal of Clinical Oncology</i> , 2005, 23, 242-244.	0.8	51
270	Onset of thymic recovery and plateau of thymic output are differentially regulated after stem cell transplantation in children. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 194-205.	2.0	42



#	ARTICLE	IF	CITATIONS
271	Experiences with haploidentical stem cell transplantation in children with acute lymphoblastic leukemia. <i>Pathologie Et Biologie</i> , 2005, 53, 159-161.	2.2	15
272	Haploidentical Stem Cell Transplantation in Children: A Comparison between Positive Selection of Stem Cells and Depletion of T- and B-Cells.. <i>Blood</i> , 2005, 106, 1420-1420.	0.6	0
273	Boosts with Highly Purified Stem Cells Can Improve Hematopoietic Regeneration after Allogeneic Transplantation from Alternative Donors.. <i>Blood</i> , 2005, 106, 2917-2917.	0.6	0
274	Analysis of Chimerism After Stem Cell Transplantation. , 2004, 91, 247-264.		4
275	Determinants of Antileukemia Effects of Allogeneic NK Cells. <i>Journal of Immunology</i> , 2004, 172, 644-650.	0.4	397
276	WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?. <i>European Journal of Haematology</i> , 2004, 73, 25-28.	1.1	24
277	Haploidentical transplantation for acute lymphoblastic leukemia in childhood. <i>Blood Reviews</i> , 2004, 18, 181-192.	2.8	76
278	Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors. <i>British Journal of Haematology</i> , 2004, 124, 72-79.	1.2	86
279	Down-regulation of protein kinase C $\delta$ by antisense oligonucleotides sensitises A549 lung cancer cells to vincristine and paclitaxel. <i>Cancer Letters</i> , 2004, 209, 177-185.	3.2	37
280	Long-term outcome after haploidentical stem cell transplantation in children. <i>Blood Cells, Molecules, and Diseases</i> , 2004, 33, 281-287.	0.6	99
281	Increasing Mixed Chimerism Is an Important Prognostic Factor for Unfavorable Outcome in Children With Acute Lymphoblastic Leukemia After Allogeneic Stem-Cell Transplantation: Possible Role For Pre-Emptive Immunotherapy?. <i>Journal of Clinical Oncology</i> , 2004, 22, 1696-1705.	0.8	231
282	Control of Fulminant Juvenile Myelomonocytic Leukemia (JMML) Relapse and Gut GvHD III $\hat{A}$ <sup>o</sup> with Purinethol Early after Unrelated Donor BMT.. <i>Blood</i> , 2004, 104, 5089-5089.	0.6	0
283	Improved Immune Reconstitution with Low Incidence of Severe Graft-Versus-Host Disease after Transplantation of CD34+ or CD133+ Enriched Stem Cells with Add-Back of Ten Million T-Cells Per Kg.. <i>Blood</i> , 2004, 104, 1239-1239.	0.6	0
284	Pediatric Patients Transplanted with Positive Selected Stem Cells from Alternative Donors Have a Low Incidence of CMV Dnaemia.. <i>Blood</i> , 2004, 104, 5192-5192.	0.6	0
285	GvHD and Engraftment after Haploidentical Stem Cell Transplantation. A Comparison of 3 Immunomagnetic Selection Procedures.. <i>Blood</i> , 2004, 104, 5019-5019.	0.6	0
286	Fatal immune-mediated pancytopenia and a TRALI-like syndrome associated with high titers of recipient-type antibodies against donor-derived peripheral blood cells after allogeneic bone marrow transplantation following dose reduced conditioning. <i>Haematologica</i> , 2004, 89, ECR12.	1.7	2
287	Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. <i>British Journal of Haematology</i> , 2003, 121, 411-418.	1.2	100
288	Risks of mortality in children admitted to the paediatric intensive care unit after haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2003, 121, 886-891.	1.2	89

#	ARTICLE	IF	CITATIONS
289	Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2003, 122, 24-29.	1.2	66
290	Identification of a novel class of human adherent CD34 <sup>+</sup> stem cells that give rise to SCID-repopulating cells. <i>Blood</i> , 2003, 101, 869-876.	0.6	100
291	Transplantation of highly purified CD34 <sup>+</sup> progenitor cells from unrelated donors in pediatric leukemia. <i>Blood</i> , 2003, 101, 1630-1636.	0.6	89
292	Distinct contributions of CD4 <sup>+</sup> and CD8 <sup>+</sup> naive and memory T-cell subsets to overall T-cell receptor repertoire complexity following transplantation of T-cell receptor-depleted CD34-selected hematopoietic progenitor cells from unrelated donors. <i>Blood</i> , 2002, 100, 1915-1918.	0.6	31
293	Quantification of T-cell receptor excision circle DNA using fluorescence resonance energy transfer and the LightCycler system. <i>Journal of Immunological Methods</i> , 2002, 271, 167-175.	0.6	34
294	Induction of drug resistance and protein kinase C genes in A2780 ovarian cancer cells after incubation with antineoplastic agents at sublethal concentrations. <i>Anticancer Research</i> , 2002, 22, 4229-32.	0.5	20
295	A prospective analysis of the pattern of immune reconstitution in a paediatric cohort following transplantation of positively selected human leucocyte antigen-disparate hematopoietic stem cells from parental donors. <i>British Journal of Haematology</i> , 2001, 114, 422-432.	1.2	85
296	Anticancer Drug-mediated Induction of Multidrug Resistance-associated Genes and Protein Kinase C Isozymes in the T-Lymphoblastoid Cell Line CCRF-CEM and in Blasts from Patients with Acute Lymphoblastic Leukemias. <i>Japanese Journal of Cancer Research</i> , 2001, 92, 896-903.	1.7	24
297	Ex Vivo Expansion of Normal Progenitor Cells from Acute Myeloid Leukemia Cell-Contaminated CD34 <sup>+</sup> Peripheral Blood Progenitor Cells after Mafosfamide Purging. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2001, 10, 777-785.	1.8	2
298	Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia. <i>British Journal of Haematology</i> , 2000, 111, 635-640.	1.2	6
299	Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia. <i>British Journal of Haematology</i> , 2000, 111, 635-640.	1.2	107
300	Evaluation of Murex CMV DNA Hybrid Capture Assay for Detection and Quantitation of Cytomegalovirus Infection in Patients following Allogeneic Stem Cell Transplantation. <i>Journal of Clinical Microbiology</i> , 1998, 36, 1333-1337.	1.8	28
301	Autologous Transplantation with Peripheral Blood Stem Cells in Children and Young Adults After Myeloablative Treatment: Nonrandomized Comparison Between GM-CSF and G-CSF for Mobilization. <i>Stem Cells and Development</i> , 1995, 4, 307-314.	1.0	14